BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29449434)

  • 21. Mechanisms of
    Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
    Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells.
    Dervieux T; Blanco JG; Krynetski EY; Vanin EF; Roussel MF; Relling MV
    Cancer Res; 2001 Aug; 61(15):5810-6. PubMed ID: 11479220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells.
    Karim H; Hashemi J; Larsson C; Moshfegh A; Fotoohi AK; Albertioni F
    Biochem Biophys Res Commun; 2011 Jul; 411(1):156-61. PubMed ID: 21723252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The associated contributions of p53 and the DNA mismatch repair protein Msh6 to spontaneous tumorigenesis.
    Young LC; Keuling AM; Lai R; Nation PN; Tron VA; Andrew SE
    Carcinogenesis; 2007 Oct; 28(10):2131-8. PubMed ID: 17615258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.
    Fotoohi AK; Lindqvist M; Peterson C; Albertioni F
    Biochem Biophys Res Commun; 2006 Apr; 343(1):208-15. PubMed ID: 16530731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
    Yang JJ; Bhojwani D; Yang W; Cai X; Stocco G; Crews K; Wang J; Morrison D; Devidas M; Hunger SP; Willman CL; Raetz EA; Pui CH; Evans WE; Relling MV; Carroll WL
    Blood; 2008 Nov; 112(10):4178-83. PubMed ID: 18768390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
    Li B; Li H; Bai Y; Kirschner-Schwabe R; Yang JJ; Chen Y; Lu G; Tzoneva G; Ma X; Wu T; Li W; Lu H; Ding L; Liang H; Huang X; Yang M; Jin L; Kang H; Chen S; Du A; Shen S; Ding J; Chen H; Chen J; von Stackelberg A; Gu L; Zhang J; Ferrando A; Tang J; Wang S; Zhou BB
    Nat Med; 2015 Jun; 21(6):563-71. PubMed ID: 25962120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia.
    Konantz M; André MC; Ebinger M; Grauer M; Wang H; Grzywna S; Rothfuss OC; Lehle S; Kustikova OS; Salih HR; Handgretinger R; Fend F; Baum C; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
    Leukemia; 2013 Jan; 27(1):56-65. PubMed ID: 22828445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia.
    Adamson PC; Poplack DG; Balis FM
    Leuk Res; 1994 Nov; 18(11):805-10. PubMed ID: 7967706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.
    Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J
    Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mismatch repair and the downstream target genes, PAX5 and Ikaros, in childhood acute lymphoblastic leukemia.
    Best A; Matheson E; Minto L; Hall AG; Irving JA
    Leuk Res; 2010 Aug; 34(8):1098-102. PubMed ID: 20233627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
    Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
    Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
    Yamane K; Schupp JE; Kinsella TJ
    Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Important role of caspase-8 for chemosensitivity of ALL cells.
    Ehrhardt H; Wachter F; Maurer M; Stahnke K; Jeremias I
    Clin Cancer Res; 2011 Dec; 17(24):7605-13. PubMed ID: 22010212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
    Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
    Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
    Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA mismatch repair protein Msh6 is required for optimal levels of ultraviolet-B-induced apoptosis in primary mouse fibroblasts.
    Young LC; Peters AC; Maeda T; Edelmann W; Kucherlapati R; Andrew SE; Tron VA
    J Invest Dermatol; 2003 Oct; 121(4):876-80. PubMed ID: 14632208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy.
    Warren DJ; Andersen A; Slørdal L
    Cancer Res; 1995 Apr; 55(8):1670-4. PubMed ID: 7712473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.